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A simple and efficient one-pot synthesis of novel polyheterocyclic benzimidazo[1,2-a]- chromeno[4,3-d]pyrimidinones 4 
via a three-component condensation of 2-aminobenzimidazole 1, aromatic aldehydes 2 and 4-hydroxy coumarin 3 catalyzed 
by Bronsted acid ionic liquid triethyl ammonium hydrogen sulphate [Et3NH][HSO4] under solvent-free conditions is 
reported. The main advantages of this protocol are short reaction time, easy work-up, operational simplicity, and excellent 
yields with high purity, without intervention of chromatography. 
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Multi-component reactions (MCRs) have proved to 
be remarkably successful in generating products in a 
single synthetic operation1,2, and are important 
owing to their synthetic efficiency3,4. In times, where 
a premium is put on speed, diversity, and efficiency 
in drug discovery process5, MCR strategies offer 
significant advantages over conventional linear-type 
syntheses. MCRs contribute to the requirements of 
an environmentally friendly process by reducing the 
number of synthetic steps, energy consumption and 
waste production. Besides this, MCRs have their 
inherent advantages of atom economy, short 
reaction time, operational simplicity, and structural 
diversity to get the goal of an ideal organic 
synthesis6,7. 
Heterocycles containing nitrogen atom are abundant 
in nature, and exhibit diverse and promising biological 
activities8. Nitrogen-bridged polyheterocycles are 
frequently found in natural products and pharmaceutical 
agents. Fused pyrimidine core structures have wide 
applications as pharmacophores, and exhibited 
antibacterial9, antiparasitic10, antiviral11, and anti-
inflammatory activities12. On the other hand, chromene 
is a ubiquitous heterocyclic scaffold and important 
pharmacophore that displays several biological 
properties such as antioxidant13, antimicrobial14, 
antitumor15, anticoagulant16 and antivascular activities17. 
Similarly, benzimidazole is an important nucleus that 
has been extensively used in medicinal chemistry, 
notable examples being the antihistaminic asterizole and 
the antiulcerative omeprazole18,19. Benzimidazoles are 
also known for their anti-inflammatory20, antibiotic21, 
anthelmintic22, anticancer23, and antiviral activities24. 
Prompted by these reports, and as a sequel to our interest 
in developing more efficient methodologies for the 
synthesis of fused polyheterocyclic compounds25-27, we 
report herein a simple, and high-yielding one-pot 
efficient protocol for the synthesis of novel 
benzimidazo[1,2-a]chromeno[4,3-d]pyrimidinones by 
using [Et3NH][HSO4] as a reusable catalyst under 
solvent-free conditions. 
Results and Discussion  
The synthesis of title compounds has been 
accomplished by synthetic sequence shown in 
Scheme I. The three-component reaction of 2-amino 
benzimidazole (1), substituted aromatic aldehydes (2), 
and 4-hydroxy coumarin (3) in presence of 20 mol% 
of Bronsted acid ionic liquid triethyl ammonium 
hydrogen sulphate [Et3NH][HSO4] (TEAHS) at 
800C for 20 min under solvent-free reaction 
conditions furnished novel 7-aryl-7,14-dihydro-6H-
benzo [4,5]imidazo- [1,2-a]chromeno[4,3-d]pyrimidin-
6-ones (4) in excellent yields (Scheme I). 
The above reaction was initially carried out in the 
presence of triethyl amine, and subsequently with 




piperidine, and PTSA catalyst at 80oC in ethanol. The 
product was isolated in 40, 35, and 55% yields 
respectively, and it took more time (100-120 min). 
Consequently, we conducted the reaction by using 
ionic liquid [Et3NH][HSO4] in ethanol solvent at 80 oC. 
The product was isolated in 75% yield, and it also 
required more time (100 min). Then, the reaction was 
carried out with [Et3NH][HSO4] catalyst in the absence 
of solvent at 80oC. To our surprise, the product yield 
increased to 95% under solvent-free reaction conditions, 
and the reaction completed within 20 min. 
The reaction was also explored by using different 
ionic liquids viz., [bmIm]BF4, [bmIm]OH, [bmIm]Br 
and [HMim]BF4. Among all the ionic liquids 
screened, [Et3NH][HSO4] was found to be superior 
with respect to the reaction time and product yield. 
Utilization of other ionic liquids was found to be quite 
unsatisfactory. TEAHS is playing the dual role of 
solvent as well as catalyst in this reaction. 
 To establish the feasibility of the strategy, and 
optimize reaction conditions, the reaction was further 
studied by increasing the catalyst loading from  
20 mol% to 30 mol%. We found that, there is no 
noticeable improvement in the yield of the desired 
product (95%), even after increasing the catalyst 
loading to 30%. We also examined the reaction by 
decreasing the catalyst loading to 10 mol%. The 
reaction resulted in low yield (85%) compared to 20 
mol % reaction (95%). The effect of temperature on 
the reaction was also observed. It is noticed that by 
increasing the temperature to 100oC, the yields are not 
improved. When the reaction was run at 600C, 
decrease in the yield (80%) was observed. Therefore, 
based on the above results, we concluded that 80 0C 
temperature, 20 min time, and 20 mol % of the 
TEAHS catalyst under solvent-free conditions is 
sufficient and optimum for the complete conversion 
of reactants into the products (Table I). 
Having established that, the best solvent and 
catalyst is TEAHS for this transformation, the another 
advantage is, it can easily be recovered after the 
completion of the reaction, and can be used in 
subsequent runs (five runs) without loss of efficiency, 
and product yield. The recovery and reusability of 
TEAHS was also investigated. After completion of 
the reaction, cold water was added to the reaction 
mixture, and the products were isolated by filtration. 
The IL was recovered by removing water under 
reduced pressure, and was reused at least for five 
times without appreciable loss of catalyst, and product 
yield (Table II). 
The effect of different substituents on the benzene 
ring of aromatic aldehydes and amines are also 
investigated. We found that, different substituted 
aromatic aldehydes, and amines take part in this one-
pot condensation, and provided the corresponding 
products in excellent yields. It has also been observed 
that, this method has the ability to tolerate a variety of 
functional groups such as electron donating methyl, 
methoxy, dimethylamino, and electron withdrawing 
chloro, bromo and nitro groups substituted on the 
aromatic ring of the aldehyde as well as on the amine. 
In all these cases, the product yields are excellent.  
A plausible mechanism for the synthesis of novel 
benzimidazo[1,2-a]chromeno- [4,3-d]pyrimidinones 










Knoevenagel condensation between aldehyde (2) and 
4-hydroxy coumarin (3) catalyzed by TEAHS. The 
resulting intermediate (5), then undergoes Michael 
type addition with 2-aminobenzimidazole (1) to 
afford the adduct (6). Subsequently, 6 undergoes 
intramolecular ring- closure followed by dehydration 
to afford title compounds (4). 
Fifteen new benzimidazo[1,2-a]chromeno[4,3-d] 
pyrimidinones (4a-o) are reported for the first time. 
The structures of all the newly synthesized 
compounds (4) are confirmed by IR, 1H NMR, 
13C NMR and mass spectral data. Elemental analyses 
confirmed the elemental composition and purity of the 
newly synthesized compounds. 
IR spectrum of compound 4a exhibited strong 
absorption bands at 3450, 1670, 1620 and 1130 cm-1 
for NH, C=O, C=N and C-O-C functional groups 
respectively. 1HNMR spectrum of 4a displayed a 
prominent peak at δ 5.66 due to ArCH proton. The NH 
proton appeared as a broad singlet at δ 8.76, which is 
D2O exchangeable. All the aromatic protons appeared 
as a complex multiplet between δ 7.00-7.83. In 13C 
NMR spectrum of 4a, ArCH carbon signal appeared at 
δ 49.34 confirming the cyclization. The mass spectrum 
of 4a displayed the molecular ion [M+H]+ peak at m/z 




 Melting points have been determined on a Fisher-
Johns melting point apparatus and are uncorrected. 
Analytical TLC has been performed on Merck 
precoated 60 F254 silica gel plates. Visualization is 
carried out by exposure to iodine vapour. IR spectra 
(KBr pellet) have been recorded on a Perkin-Elmer 
BX series FT-IR spectrometer. 1H NMR spectra are 
recorded on a Bruker 300 MHz spectrometer. 13C 
NMR spectra are recorded on a Bruker 75 MHz 
spectrometer. Chemical shift values are given in  
ppm with tetramethyl silane as an internal standard. 
ESI mass spectra are recorded on a Agilent LC-MSD 
mass spectrometer. Elemental analyses are performed 
on a Carlo Erba 106 and Perkin-Elmer model 240 
analyzers. 
General procedure for the synthesis of 7-aryl-
7,14-dihydro-6H-benzo[4,5]imidazo [1,2-a] chromeno 
[4,3-d]pyrimidin-6-ones (4a-o) 
To a mixture of 2-amino benzimidazole (1a, 1 
mmol), aromatic aldehyde (2a, 1 mmol) and 4-
hydroxy coumarin (3a, 1 mmol), 20 mol % [Et3NH] 
[HSO4] was added, and the reaction mixture was 
stirred at 80oC under solvent-free conditions for  
20 min. The termination of the reaction was monitored 
by TLC. After completion of the reaction, the reaction 
mixture was cooled to room temperature, water was 
added, and the contents are stirred for 5 min. The 
solid thus obtained was removed by filtration, and 
recrystallized from ethanol to afford the pure product 
4a. The water was removed from filtrate under 
Table I — Effect of different catalysts and ionic liquids on the synthesis of benzimidazo[1,2-a]- 
 chromeno[4,3-d]pyrimidinones 4 
Entry Catalyst Catalyst loading (mol%) Solvent Temp(oC) Time (min) Yield(%)a 
1 Et3N 20 EtOH 80 120 40 
2 Piperidine 20 EtOH 80 100 35 
3 p-TSA 20 EtOH 80 100 55 
4 [Et3NH]HSO4 20 EtOH 80 100 75 
5  [Et3NH]HSO4 20 solvent- free 80 20 95 
6 [bmIm]BF4 20 solvent- free 80 40 58 
7 [bmIm]OH 20 solvent- free 80 25 45 
8 [bmIm]Br 20 solvent- free 80 50 30 
9 [HMIm]BF4 20 solvent -free 80 20 65 
10 [Et3NH][HSO4] 30 solvent- free 80 20 95 
11 [Et3NH][HSO4] 10 solvent -free 80 20 85 
12 [Et3NH][HSO4] 20 solvent -free 100 20 95 
13 [Et3NH][HSO4] 20 solvent -free 60 20 80 
a Optimized and isolated yields. 
 
Table II — Recycling of IL [Et3NH][HSO4] 
Run IL recycled (in mL) Yield (%) a 
1 5 95 
2 5 95 
3 4.7 94 
4 4.5 92 
5 4.0 90 
a Isolation yields 
 




reduced pressure to recover [Et3NH][HSO4], which 
was then reused in subsequent cycles. Compounds 
(4b-4o) have been synthesized by adopting similar 
procedure. 
7-Phenyl-7,14-dihydro-6H-benzo[4,5]imidazo 
[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4a) Orange 
solid, yield 95%, m.p. 192-94oC, IR (KBr): 3450 
(NH), 1670 (CO), 1620 (C=N), 1130 (COC) cm-1; 1H 
NMR (300 MHz, CDCl3): δ 5.66 (s, 1H, CH), 7.00-
7.83 (m, 13H, Ar-H), 8.76 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 49.34, 
99.45, 114.35, 115.43, 115.98, 121.76, 123.10, 
123.68,125.24, 125.98, 126.98, 127.89, 128.03, 
128.98, 129.05, 129.87, 134.65, 137.45, 138.97, 
149.56, 150.45, 152.76, 165.45; ESI-MS: m/z 366 
[M+H]+ . Anal.cacld for C23H15N3O2: C, 75.61; H, 4.10; 
N, 11.50 % Found: C, 75.64; H, 4.13; N, 11.52 %. 
7-(P-Tolyl)-7,14-dihydro-6H-benzo[4,5]imidazo 
[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4b) 
Orange solid, yield 95%, m.p. 182-84oC, IR (KBr): 
3456 (NH), 1674 (CO), 1626 (C=N), 1135 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 2.35 ( s, 3H, CH3), 
5.68 (s, 1H, CH), 7.06-7.86 (m, 12H, Ar-H), 8.76 (bs, 
1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 24.12, 49.37, 99.49, 114.69, 115.49, 
116.45, 122.16, 123.23, 123.72,125.24, 126.01, 
126.99, 127.92, 128.09, 129.01, 129.55, 130.02, 
134.65, 137.55, 139.02, 149.89, 150.85, 152.36, 
166.02; ESI-MS: m/z 380 [M+H]+ . Anal.cacld for 
C24H17N3O2: C, 75.98; H, 4.48; N, 11.08 % Found: C, 




Orange solid, yield 95%, m.p. 187-89oC, IR (KBr): 
3454 (NH), 1673 ( CO), 1625 (C=N), 1133 (COC) 
cm-1; 1H NMR (300 MHz, CDCl3): δ 3.80 (s, 3H, 
OCH3), 5.66 (s, 1H, CH), 7.06-7.89 (m, 12H, Ar-H), 
8.78 (bs, 1H, NH, D2O exchangeable); 13C NMR 
(75MHz, CDCl3): δ 49.39, 63.46, 99.99, 114.76, 
115.59, 117.47, 122.56, 123.65, 123.92,125.54, 
126.11,127.23, 127.92, 128.19, 129.10, 129.68, 
130.12, 134.76, 137.98, 139.02, 150.02, 150.85, 
152.66, 166.12; ESI-MS: m/z 396 [M+H]+ . Anal. 
cacld for C24H17N3O3: C, 72.91; H, 4.30; N, 10.63 % 
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Scheme II — Plausible mechanism for the synthesis of novel benzimidazo[1,2-a]chromeno-[4,3-d]pyrimidinones 
 







Orange solid, yield 95%, m.p. 215-17oC, IR (KBr): 
3460 (NH), 1672 (CO), 1625 (C=N), 1138 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 2.54 (s, 6H, N(CH3)2), 
5.66 (s, 1H, CH), 7.06-7.90 (m, 12H, Ar-H), 8.78 (bs, 
1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 48.32, 50.10, 51.79, 100.13, 114.91, 
115.86, 117.88, 122.81, 123.98, 124.02, 125.87, 
126.53,127.51, 127.98, 128.43, 129.30, 130.12, 
130.45, 134.76, 138.01, 139.32, 150.08, 150.80, 
154.16, 166.22; ESI-MS: m/z 409. [M+H]+ . 
Anal.cacld for C25H20N4O2: C, 73.52; H, 4.90; N, 
13.72 % Found: C, 73.56; H, 4.93; N, 13.75 %. 
7-(4-Chlorophenyl)-7,14-dihydro-6H-benzo[4,5] 
imidazo[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4e) 
Orange solid, yield 94%, m.p. 238-40oC, IR (KBr): 
3459 (NH), 1672 (CO), 1626 (C=N), 1134 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 5.69 (s, 1H, CH), 
7.06-7.94 (m, 12H, Ar-H), 8.78 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 50.10, 
100.13, 114.89, 115.87, 118.07, 122.76, 123.88, 
123.90,125.87, 126.33,127.85, 127.99, 128.55, 
129.39, 130.20, 130.62, 134.89, 138.01, 139.32, 150.12, 
150.95, 153.79, 166.30; ESI-MS: m/z 400 [M+H]+ . 
Anal.cacld for C23H14ClN3O2: C, 69.17; H, 3.50; N, 
10.52 % Found: C, 69.14; H, 3.53; N, 10.55%. 
7-(4-Bromophenyl)-7,14-dihydro-6H-benzo[4,5] 
imidazo[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4f) 
Brown solid, yield 94%, m.p. 272-74oC, IR (KBr): 
3458 (NH), 1669 (CO), 1621 (C=N), 1136 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 5.68 (s, 1H, CH), 
7.06-7.92 (m, 12H, Ar-H), 8.75 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 50.02, 
100.03, 114.86, 115.79, 117.67, 122.76, 123.78, 
123.92,125.67, 126.43,127.45, 127.92, 128.35, 
129.30, 130.02, 130.22, 134.76, 137.98, 139.32, 
150.02, 150.85, 153.76, 166.32; ESI-MS: m/z 444 
[M+H]+ . Anal.cacld for C23H14BrN3O2: C, 62.30;  




Orange solid, yield 94%, m.p. 250-52oC, IR (KBr): 
3461 (NH), 1671 (CO), 1625 (C=N), 1136 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 5.68 (s, 1H, CH), 7.02-
7.90 (m, 12H, Ar-H), 8.79 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 50.13, 
101.03, 113.89, 115.47, 118.67, 123.06, 123.90, 
124.10,125.97, 126.13,128.05, 128.99, 129.15, 129.79, 
130.00, 131.32, 135.19, 138.11, 139.52, 150.42, 151.15, 
154.09, 166.51; ESI-MS: m/z 411 [M+H]+ . Anal.cacld 
for C23H14N4O4: C, 67.31; H, 3.41; N, 13.65 % Found: 
C, 67.34; H, 3.45; N, 13.62 %. 
10-Methyl-7-phenyl-7,14-dihydro-6H-benzo[4,5] 
imidazo[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4h) 
Orange solid, yield 95%, m.p. 208-10oC, IR (KBr): 
3458 (NH), 1672 (CO), 1623 (C=N), 1132 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 2.36 ( s, 3H, CH3), 
5.69 (s, 1H, CH), 7.02-7.96 (m, 12H, Ar-H), 8.78 (bs, 
1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 24.22, 49.48, 99.89, 115.09, 115.89, 
116.65, 122.86, 123.13, 123.94, 126.04, 126.11,  
127.09, 127.98, 128.19, 129.11, 130.05, 130.82, 
134.85, 137.95, 139.12, 149.89, 151.01, 152.36, 
167.02; ESI-MS: m/z 380 [M+H]+ . Anal.cacld for 
C24H17N3O2: C, 75.98; H, 4.48; N, 11.08 % Found: C, 




Orange solid, yield 95%, m.p. 221-23oC, IR (KBr): 
3457 (NH), 1676 ( CO), 1626 (C=N), 1135 (COC) 
cm-1; 1H NMR (300 MHz, CDCl3): δ 2.34 (s, 3H, 
CH3), 3.82 (s, 3H, OCH3), 5.67 (s, 1H, CH), 7.09-7.93 
(m, 11H, Ar-H), 8.79 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 25.16, 
49.69, 63.36, 100.01, 114.46, 115.39, 116.87, 123.16, 
123.85, 124.12, 125.64, 126.19, 127.13, 127.98, 
128.29, 129.10, 129.81, 131.10, 134.88, 138.08, 
139.22, 150.22, 151.15, 152.76, 166.32; ESI-MS: m/z 
410 [M+H]+ . Anal.cacld for C25H19N3O3: C, 73.34; 





Orange solid, yield 94%, m.p. 260-62oC, IR (KBr): 
3458 (NH), 1676 (CO), 1628 (C=N), 1137 (COC) cm-
1; 1H NMR (300 MHz, CDCl3): δ 2.36 ( s, 3H, CH3), 
5.69 (s, 1H, CH), 7.03-7.90 (m, 11H, Ar-H), 8.78 (bs, 
1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 24.32, 49.77, 100.02, 114.75, 115.29, 
117.25, 122.36, 123.13, 123.92, 125.14, 126.21, 
127.02, 127.95, 128.19, 129.23, 129.75, 131.02, 
134.65, 137.35, 140.01, 149.80, 151.05, 152.39, 
166.12; ESI-MS: m/z 414 [M+H]+ . Anal.cacld for 
C24H16ClN3O2: C, 69.73; H, 3.87; N, 10.16 % Found: 
C, 69.76; H, 3.84; N, 10.14%. 







Brown solid, yield 94%, m.p. 280-82oC, IR (KBr): 
3457 (NH), 1675 (CO), 1625 (C=N), 1135 (COC) cm-1; 
1H NMR (300 MHz, CDCl3): δ 2.34 ( s, 3H, CH3), 
5.68 (s, 1H, CH), 7.01-7.85 (m, 11H, Ar-H), 8.76 (bs, 
1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 24.29, 49.67, 99.89, 114.54, 115.20, 
117.15, 122.26, 122.93, 123.32, 125.25, 126.11, 
127.22, 128.01, 128.59, 129.34, 129.85, 131.32, 
134.87, 137.41, 140.21, 149.80, 151.35, 152.55, 
166.38; ESI-MS: m/z 458 [M+H]+ . Anal.cacld for 
C24H16BrN3O2: C, 63.01; H, 3.50; N, 9.19% Found: C, 
C, 63.04; H, 3.53; N, 9.15%. 
10-Chloro-7-phenyl-7,14-dihydro-6H-benzo[4,5] 
imidazo[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4l) 
Orange solid, yield 94%, m.p. 243-45oC, IR (KBr): 
3456 (NH), 1673 (CO), 1625 (C=N), 1133 (COC) cm-
1; 1H NMR (300 MHz, CDCl3): δ 5.67 (s, 1H, CH), 
7.04-7.98 (m, 12H, Ar-H), 8.79 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 50.12, 
100.23, 114.92, 115.77, 118.58, 122.91, 123.25, 
124.02, 125.37, 126.33, 127.65, 128.01, 128.65, 
129.58, 131.00, 130.91, 134.79, 138.11, 139.55, 
150.22, 151.21, 153.85, 166.56; ESI-MS: m/z 400 
[M+H]+ . Anal.cacld for C23H14ClN3O2: C, 69.17; H, 




Orange solid, yield 94%, m.p. 266-68oC, IR (KBr): 
3461 (NH), 1672 (CO), 1625 (C=N), 1137 (COC) cm-
1; 1H NMR (300 MHz, CDCl3): δ 2.34 ( s, 3H, CH3), 
5.69 (s, 1H, CH), 7.06-8.04 (m, 11H, Ar-H), 8.80  
(s, 1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 24.87, 49.39, 99.59, 114.65, 115.61, 
116.87, 122.21, 123.45, 123.87,125.34, 126.34, 
126.99, 127.99, 128.10, 129.32, 129.59, 130.08, 
134.35, 137.55, 139.22, 149.91, 150.86, 152.36, 
166.32; ESI-MS: m/z 414 [M+H]+ . Anal.cacld for 
C24H16ClN3O2: C, 69.73; H, 3.87; N, 10.16 % Found: 
C, 69.71; H, 3.89; N, 10.13 %. 
10-Bromo-7-phenyl-7,14-dihydro-6H-benzo[4,5] 
imidazo[1,2-a]chromeno[4,3-d]pyrimidin-6-one, (4n) 
Brown solid, yield 94%, m.p. 276-78oC, IR (KBr): 
3456 (NH), 1667 (CO), 1623 (C=N), 1134 (COC) cm-
1; 1H NMR (300 MHz, CDCl3): δ 5.66 (s, 1H, CH), 
7.04-7.96 (m, 12H, Ar-H), 8.74 (bs, 1H, NH, D2O 
exchangeable); 13C NMR (75MHz, CDCl3): δ 50.21, 
100.23, 114.79, 116.79, 117.47, 121.76, 122.78, 
123.42,125.69, 126.43, 127.76, 128.01, 128.39, 
129.31, 130.02, 130.52, 135.16, 138.01, 139.22, 
150.22, 151.32, 153.56, 166.39; ESI-MS: m/z 444 
[M+H]+ . Anal.cacld for C23H14BrN3O2: C, 62.30;  





Brown solid, yield 94%, m.p. 286-88oC, IR (KBr): 
3456 (NH), 1674 (CO), 1628 (C=N), 1137 (COC) cm-
1; 1H NMR (300 MHz, CDCl3): δ 3.81 (s, 3H, OCH3), 
5.68 (s, 1H, CH), 7.06-7.94 (m, 11H, Ar-H), 8.78  
(s, 1H, NH, D2O exchangeable); 13C NMR (75MHz, 
CDCl3): δ 50.02, 63.79, 100.01, 114.91, 115.39, 
117.57, 123.01, 123.69, 124.05,125.59, 126.18, 
127.43, 127.93, 128.29, 129.45, 129.78, 130.02, 
134.57, 138.05, 139.06, 150.12, 150.80, 152.77, 
166.52; ESI-MS: m/z 474 [M+H]+ . Anal.cacld for 
C24H16BrN3O3: C, 60.88; H, 3.38; N, 8.87 % Found: 
C, 60.86; H, 3.35; N, 8.89 %. 
 
Conclusion 
In conclusion, the present procedure that uses ionic 
liquid[Et3NH][HSO4] provides a fast and highly 
efficient methodology for the synthesis of novel 
polyheterocyclic benzimidazo[1,2-a]- chromeno[4,3-
d]pyrimidinones under solvent-free conditions. This 
protocol avoids the usage of hazardous organic 
solvents, and has several advantages such as high 
yields, convenient operation, easy-workup, catalytic 
reusability, and no by-products formation. The 
products are isolated in pure form by recrystallization, 
without intervention of chromatography, making the 
technology practical, easy to perform and facile.  
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